What is the dosage of Dayvigo?

In December 2019, the U.S. Food and Drug Administration (FDA) approved Eisai’s (Dayvigo, lemborexant) to be marketed for the treatment of insomnia in adults. The active ingredient of Dayvigo, lemborexant, is a dual orexin receptor antagonist. Lemborexant inhibits orexin neurotransmission by competitively binding to the orexin-1 receptor (OX1R) and the orexin-2 receptor (OX2R) to regulate sleep-wake rhythms. So, what is the dosage of Dayvigo?

Dayvigo usage and dosage

5 mg, take no more than once each night before bed, at least 7 hours before scheduled awakening time. The dose may be increased based on clinical response and tolerability to the maximum recommended dose of 10 mg. If taken with or shortly after a meal, the time to sleep may be delayed.

Dosage recommendations for leborexan in patients with hepatic impairment

In patients with moderate hepatic impairment, the maximum recommended dose of this product is 5 mg, not to exceed once per night. This product is not recommended for patients with severe liver damage.

Recommendations for patients with compromised respiratory function

If prescribed to patients with compromised respiratory function, the effects of DAYVIGO on respiratory function should be considered. This product has not been studied in patients with moderate to severe obstructive sleep apnea (OSA) or chronic obstructive pulmonary disease (COPD).

Also need to pay attention

Recently, many patients have reported that there are many rumors on the Internet that as long as doubling the dose can achieve better therapeutic effects, or that just reducing the dose of the drug can avoid the occurrence of side effects, these are unfounded. Patients should still take the correct medication according to the doctor's instructions to truly benefit themselves.

Recommended related articles: